- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01460095
Improving Access to HbA1c in Sub Saharan Africa (IA3)
Improving Access to HbA1c Measurement in Sub-Saharan Africa
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective is to determine whether the introduction of routine affordable HbA1c determination with immediate feedback to patients and relevant education in an underserved population without any further intervention on drug supply would significantly improve diabetes control. As this will be an after-versus-before type study, each patient will be his own control.
Study setting The study will be undertaken in 10 existing diabetes care centre in two countries, including 4 regional centers in Guinea, a West African country of 10 millions inhabitants, and 6 regional centers in Cameroon, a Central African country of 18 million inhabitants.
The health districts covered in Guinea are Conakry, Labe, Kankan and Boke each being situated in a different ecological and cultural areas. In Cameroon, the health districts covered are Biyem Assi in Yaoundé, Garoua, Limbe, Ebolowa, Bamenda, Bafoussam also covering the 4 ecological zone of Cameroon.
All these health districts have existing diabetes care centre with trained personnel run in public hospital with prices and medicine affordable to most of the population covered. However, none of these centers have an HbA1c machine, and diabetes control is mainly evaluated using blood glucose, most often fasting.
Target population The aim is to provide the service to all patients followed in the selected centers at low cost however the first eligible 1000 patients will be included in the formal intervention free of charge.
Eligibility All patients with a physician-confirmed diagnosis of diabetes and who have been followed in the diabetes centre for at least one year are eligible Sample size In order to detect a difference of 1 unit (1% glycated haemoglobin) between to samples with a standard deviation of 1.2%, alpha coefficient of 0.001 and 0.8 power using a two-sided test, a minimum population of 80 subjects is required. The minimum sample size if alpha is 0.01 is 55 subjects. We therefore decided a sample size of 100 patients per centre in order to be able to analyze data taking into account center or physician effect. It thus give an overall sample size of 1000 subjects.
Sampling method We will use a systematic sampling, enrolling consecutive eligible patients volunteering to participate until completion of the sample size in each individual centre.
Inclusion All eligible patients, not intending to migrate from the study site within 1 year, and volunteering to participate will be enrolled. At inclusion the following will record of demographic characteristics, past medical history, characteristics of diabetes, evaluation of patient knowledge, and measurement of anthropometric characteristics, blood pressure, haematocrit, HbA1c, and urinary albumin excretion at baseline.
Intervention and follow up:
Data will be collected using a clinical record form designated to this effect. The intervention will consist of the measurement of HbA1c at baseline, 3, and 6 months with immediate feedback to patients and provision of targeted education after each determination, on level, significance, and targets.
Treatment will follow usual guidelines with no additional intervention. Adjustment of treatment will be done by the health care personnel in a treat-to-target fashion. No change in drug supply will be introduced. No specific recommendation will be given concerning the frequency of hospital visit between the study visits at baseline, month 3, 6, and 12. Each centre will continue with usual follow up frequency.
At month 12, we will repeat the evaluation of patient knowledge, and the measurement of anthropometric characteristics, blood pressure, haematocrit, HbA1c, and urinary albumin excretion for comparison to baseline.
Timeframe
- Start date: Month 7
- End of enrollment: Month 12
- End of follow-up of last patient enrolled: Month 24
Outcome measures
Primary outcome: Change in HbA1c from baseline to 12 months
Secondary outcomes:
- Change in percentage of patients at HbA1c target from baseline to 12 months
- Change in urinary albumin excretion from baseline to 12 months The other measures will serve for the interpretation of data Deliverables
- Dataset for each centre between Month 24 and Month 26
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bafoussam, Cameroon
- Bafoussam District Hospital
-
-
Centre
-
Yaounde, Centre, Cameroon
- Yaoundé Central Hospital
-
-
North
-
Garoua, North, Cameroon
- Garoua Regional Hospital
-
-
North West
-
Bamenda, North West, Cameroon
- Bamenda Regional Hospital
-
-
South West
-
Buea, South West, Cameroon
- Buea Regional Hospital
-
-
-
-
-
Boke, Guinea
- Boke Regional Hospital
-
Conakry, Guinea
- CHU Donka
-
Kankan, Guinea
- Kankan Regional Hospital
-
Labe, Guinea
- Labe regional Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed diabetes mellitus irrespective of type
- Patients who have been followed regularly for at least one year prior to inclusion in the target health facilities
- Adult age (18 years and over)
Exclusion Criteria:
- Individuals planning to migrate from study sites within one year
- Any intercurrent acute illness
- Enrollment in any other concomitant intervention study
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HbA1c measurement and education
3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
|
three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
one year change in glycated haemoglobin (HbA1c)
Time Frame: Baseline and 12 months
|
Baseline to 12 months individual change in HbA1c level
|
Baseline and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
One-year change in proportion of patients reaching HbA1c targets
Time Frame: Baseline and 12 months
|
Baseline to 12 months change in proportion of patients reaching HbA1c targets in each participating centre and in the overall population
|
Baseline and 12 months
|
One-year change in urinary albumin excretion
Time Frame: Baseline and 12 months
|
Baseline to 12 months individual change in early morning sample urinary albumin excretion
|
Baseline and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eugene Sobngwi, MD, PhD, Newcastle University, UK and Yaounde Central Hospital, Cameroon
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LT07-135 (International Diabetes Federation)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on HbA1c measurement and education
-
Centre d'Etudes et de Recherche pour l'Intensification...CompletedType 2 DiabetesFrance, Belgium
-
GULIN FINDIKOGLUCompletedDiabetes Mellitus, Type 2 | Gait Disorder, SensorimotorTurkey
-
Indiana UniversityTerminatedDiabetes Mellitus | Bacterial Infections | Wound | Infected Ulcer of SkinUnited States
-
The University of Hong KongActive, not recruitingDiabetes Mellitus | Pre DiabetesHong Kong
-
University of Maryland, BaltimoreCompleted
-
Abbott Diabetes CareActive, not recruiting
-
University of Maryland, BaltimoreTerminated
-
Nova BiomedicalCompletedKidney Diseases | Diabetes Mellitus | Metabolic DiseaseUnited States
-
The University of Texas at ArlingtonColumbia University; National Institute on Minority Health and Health Disparities... and other collaboratorsCompleted
-
Northwell HealthCompleted